Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib

Noelia Purroy; Yuzhou Evelyn Tong; Camilla K. Lemvigh; Nicoletta Cieri; Shuqiang Li; Erin M. Parry; Wandi Zhang; Laura Z. Rassenti; Thomas J. Kipps; Susan L. Slager; Neil Elliot Kay; Connie Lesnick; Tait D Shanafelt; Paolo Ghia; Lydia Scarfò; Kenneth J. Livak; Peter V. Kharchenko; Donna S. Neuberg; Lars Rønn Olsen; Jean Fan; Satyen H. Gohil; Catherine J. Wu

doi:10.1182/blood.2021013926

Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib

Noelia Purroy, Yuzhou Evelyn Tong, Camilla K. Lemvigh, Nicoletta Cieri, Shuqiang Li, Erin M. Parry, Wandi Zhang, Laura Z. Rassenti, Thomas J. Kipps, Susan L. Slager, Neil Elliot Kay, Connie Lesnick, Tait D Shanafelt, Paolo Ghia, Lydia Scarfò, Kenneth J. Livak, Peter V. Kharchenko, Donna S. Neuberg, Lars Rønn Olsen, Jean FanSatyen H. Gohil, Catherine J. Wu

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	2252-2256
Number of pages	5
Journal	Blood
Volume	139
Issue number	14
DOIs	https://doi.org/10.1182/blood.2021013926
State	Published - Apr 7 2022

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood.2021013926

Cite this

Purroy, N., Tong, Y. E., Lemvigh, C. K., Cieri, N., Li, S., Parry, E. M., Zhang, W., Rassenti, L. Z., Kipps, T. J., Slager, S. L., Kay, N. E., Lesnick, C., Shanafelt, T. D., Ghia, P., Scarfò, L., Livak, K. J., Kharchenko, P. V., Neuberg, D. S., Olsen, L. R., ... Wu, C. J. (2022). Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib. Blood, 139(14), 2252-2256. https://doi.org/10.1182/blood.2021013926

Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib. / Purroy, Noelia; Tong, Yuzhou Evelyn; Lemvigh, Camilla K.; Cieri, Nicoletta; Li, Shuqiang; Parry, Erin M.; Zhang, Wandi; Rassenti, Laura Z.; Kipps, Thomas J.; Slager, Susan L.; Kay, Neil Elliot; Lesnick, Connie; Shanafelt, Tait D; Ghia, Paolo; Scarfò, Lydia; Livak, Kenneth J.; Kharchenko, Peter V.; Neuberg, Donna S.; Olsen, Lars Rønn; Fan, Jean; Gohil, Satyen H.; Wu, Catherine J.

In: Blood, Vol. 139, No. 14, 07.04.2022, p. 2252-2256.

Research output: Contribution to journal › Letter › peer-review

Purroy, N, Tong, YE, Lemvigh, CK, Cieri, N, Li, S, Parry, EM, Zhang, W, Rassenti, LZ, Kipps, TJ, Slager, SL , Kay, NE, Lesnick, C, Shanafelt, TD, Ghia, P, Scarfò, L, Livak, KJ, Kharchenko, PV, Neuberg, DS, Olsen, LR, Fan, J, Gohil, SH & Wu, CJ 2022, 'Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib', Blood, vol. 139, no. 14, pp. 2252-2256. https://doi.org/10.1182/blood.2021013926

Purroy, Noelia ; Tong, Yuzhou Evelyn ; Lemvigh, Camilla K. ; Cieri, Nicoletta ; Li, Shuqiang ; Parry, Erin M. ; Zhang, Wandi ; Rassenti, Laura Z. ; Kipps, Thomas J. ; Slager, Susan L. ; Kay, Neil Elliot ; Lesnick, Connie ; Shanafelt, Tait D ; Ghia, Paolo ; Scarfò, Lydia ; Livak, Kenneth J. ; Kharchenko, Peter V. ; Neuberg, Donna S. ; Olsen, Lars Rønn ; Fan, Jean ; Gohil, Satyen H. ; Wu, Catherine J. / Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib. In: Blood. 2022 ; Vol. 139, No. 14. pp. 2252-2256.

@article{adf35866533743a8b425db9f850b3f59,

title = "Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib",

author = "Noelia Purroy and Tong, {Yuzhou Evelyn} and Lemvigh, {Camilla K.} and Nicoletta Cieri and Shuqiang Li and Parry, {Erin M.} and Wandi Zhang and Rassenti, {Laura Z.} and Kipps, {Thomas J.} and Slager, {Susan L.} and Kay, {Neil Elliot} and Connie Lesnick and Shanafelt, {Tait D} and Paolo Ghia and Lydia Scarf{\`o} and Livak, {Kenneth J.} and Kharchenko, {Peter V.} and Neuberg, {Donna S.} and Olsen, {Lars R{\o}nn} and Jean Fan and Gohil, {Satyen H.} and Wu, {Catherine J.}",

note = "Funding Information: This work was supported, in part, by National Institutes of Health (NIH), National Cancer Institute (NCI) grants 5P01CA081534-14, P01CA206978, R01CA216273, and UG1CA233338. C.J.W. acknowledges support from the CLL Global Research Foundation. S.H.G. was supported by a Kay Kendall Leukaemia Fund Fellowship. E.M.P. acknowledges research funding from the Doris Duke Charitable Foundation (Physician-Scientist Fellowship), a Conquer Cancer (The ASCO Foundation) Young Investigator Award, and Dana-Farber Flames FLAIR. J.F. received support from the NIH, National Institute of General Medical Science under award R35GM142889. P.G. was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC), Milan, Italy (Special Program on Metastatic Disease; 5 per mille #21198), and ERA NET TRANSCAN-2 Joint Transnational Call for Proposals: JTC 2016 (project #179 NOVEL), project code (MIS) 5041673. S.L. is supported by an NCI Research Specialist Award (R50CA251956). Funding Information: The authors thank Jerome Ritz and the DFCI Pasquarello Tissue Bank in Hematologic Malignancies for prospective collection and processing of blood samples from healthy donors. This work was supported, in part, by National Institutes of Health (NIH), National Cancer Institute (NCI) grants 5P01CA081534-14, P01CA206978, R01CA216273, and UG1CA233338. C.J.W. acknowledges support from the CLL Global Research Foundation. S.H.G. was supported by a Kay Kendall Leukaemia Fund Fellowship. E.M.P. acknowledges research funding from the Doris Duke Charitable Foundation (Physician-Scientist Fellowship), a Conquer Cancer (The ASCO Foundation) Young Investigator Award, and Dana-Farber Flames FLAIR. J.F. received support from the NIH, National Institute of General Medical Science under award R35GM142889. P.G. was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC), Milan, Italy (Special Program on Metastatic Disease; 5 per mille #21198), and ERA NET TRANSCAN-2 Joint Transnational Call for Proposals: JTC 2016 (project #179 NOVEL), project code (MIS) 5041673. S.L. is supported by an NCI Research Specialist Award (R50CA251956). Funding Information: Conflict-of-interest disclosure: N.P. is currently an employee of AstraZeneca; C.J.W. holds equity in BioNTech, Inc. and receives research funding from Pharmacyclics. S.H.G. has received speaker fees from Janssen UK and travel and honoraria from AbbVie and provides research consultancy for Novalgen Limited. P.G. has received honoraria from AbbVie, AstraZeneca, ArQule MSD, BeiGene, Celgene/Juno/BMS, Janssen, Loxo/Lilly, and Roche and research funding from AbbVie, AstraZeneca, Janssen, and Sunesis. P.V.K serves on the scientific advisory boards of Celsius Therapeutics Inc. and Biomage Inc. N.E.K. serves on the advisory boards of AbbVie, Astra Zeneca, Behring, Cytomx Therapy, Dava Oncology, Janssen, Juno Therapeutics, Oncotracker, Pharmacyclics and Targeted Oncology and on the data safety monitoring committees of Agios Pharm, AstraZeneca, BMS-Celgene, Cytomx Therapeutics, Janssen, Morpho-sys, and Rigel and research funding from AbbVie, Acerta Pharma, Bristol Meyer Squib, Celgene, Genentech, MEI Pharma, Pharmacyclics, Sunesis, TG Therapeutics, and Tolero Pharmaceuticals. L.S. has received honoraria from AbbVie, AstraZeneca, Janssen and travel funding from Janssen. T.D.S. received institutional research support from Genentech and Phamacyclics. The remaining authors declare no competing financial interests.",

year = "2022",

month = apr,

day = "7",

doi = "10.1182/blood.2021013926",

language = "English (US)",

volume = "139",

pages = "2252--2256",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "14",

}

TY - JOUR

T1 - Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib

AU - Purroy, Noelia

AU - Tong, Yuzhou Evelyn

AU - Lemvigh, Camilla K.

AU - Cieri, Nicoletta

AU - Li, Shuqiang

AU - Parry, Erin M.

AU - Zhang, Wandi

AU - Rassenti, Laura Z.

AU - Kipps, Thomas J.

AU - Slager, Susan L.

AU - Kay, Neil Elliot

AU - Lesnick, Connie

AU - Shanafelt, Tait D

AU - Ghia, Paolo

AU - Scarfò, Lydia

AU - Livak, Kenneth J.

AU - Kharchenko, Peter V.

AU - Neuberg, Donna S.

AU - Olsen, Lars Rønn

AU - Fan, Jean

AU - Gohil, Satyen H.

AU - Wu, Catherine J.

N1 - Funding Information: This work was supported, in part, by National Institutes of Health (NIH), National Cancer Institute (NCI) grants 5P01CA081534-14, P01CA206978, R01CA216273, and UG1CA233338. C.J.W. acknowledges support from the CLL Global Research Foundation. S.H.G. was supported by a Kay Kendall Leukaemia Fund Fellowship. E.M.P. acknowledges research funding from the Doris Duke Charitable Foundation (Physician-Scientist Fellowship), a Conquer Cancer (The ASCO Foundation) Young Investigator Award, and Dana-Farber Flames FLAIR. J.F. received support from the NIH, National Institute of General Medical Science under award R35GM142889. P.G. was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC), Milan, Italy (Special Program on Metastatic Disease; 5 per mille #21198), and ERA NET TRANSCAN-2 Joint Transnational Call for Proposals: JTC 2016 (project #179 NOVEL), project code (MIS) 5041673. S.L. is supported by an NCI Research Specialist Award (R50CA251956). Funding Information: The authors thank Jerome Ritz and the DFCI Pasquarello Tissue Bank in Hematologic Malignancies for prospective collection and processing of blood samples from healthy donors. This work was supported, in part, by National Institutes of Health (NIH), National Cancer Institute (NCI) grants 5P01CA081534-14, P01CA206978, R01CA216273, and UG1CA233338. C.J.W. acknowledges support from the CLL Global Research Foundation. S.H.G. was supported by a Kay Kendall Leukaemia Fund Fellowship. E.M.P. acknowledges research funding from the Doris Duke Charitable Foundation (Physician-Scientist Fellowship), a Conquer Cancer (The ASCO Foundation) Young Investigator Award, and Dana-Farber Flames FLAIR. J.F. received support from the NIH, National Institute of General Medical Science under award R35GM142889. P.G. was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC), Milan, Italy (Special Program on Metastatic Disease; 5 per mille #21198), and ERA NET TRANSCAN-2 Joint Transnational Call for Proposals: JTC 2016 (project #179 NOVEL), project code (MIS) 5041673. S.L. is supported by an NCI Research Specialist Award (R50CA251956). Funding Information: Conflict-of-interest disclosure: N.P. is currently an employee of AstraZeneca; C.J.W. holds equity in BioNTech, Inc. and receives research funding from Pharmacyclics. S.H.G. has received speaker fees from Janssen UK and travel and honoraria from AbbVie and provides research consultancy for Novalgen Limited. P.G. has received honoraria from AbbVie, AstraZeneca, ArQule MSD, BeiGene, Celgene/Juno/BMS, Janssen, Loxo/Lilly, and Roche and research funding from AbbVie, AstraZeneca, Janssen, and Sunesis. P.V.K serves on the scientific advisory boards of Celsius Therapeutics Inc. and Biomage Inc. N.E.K. serves on the advisory boards of AbbVie, Astra Zeneca, Behring, Cytomx Therapy, Dava Oncology, Janssen, Juno Therapeutics, Oncotracker, Pharmacyclics and Targeted Oncology and on the data safety monitoring committees of Agios Pharm, AstraZeneca, BMS-Celgene, Cytomx Therapeutics, Janssen, Morpho-sys, and Rigel and research funding from AbbVie, Acerta Pharma, Bristol Meyer Squib, Celgene, Genentech, MEI Pharma, Pharmacyclics, Sunesis, TG Therapeutics, and Tolero Pharmaceuticals. L.S. has received honoraria from AbbVie, AstraZeneca, Janssen and travel funding from Janssen. T.D.S. received institutional research support from Genentech and Phamacyclics. The remaining authors declare no competing financial interests.

PY - 2022/4/7

Y1 - 2022/4/7

UR - http://www.scopus.com/inward/record.url?scp=85127488881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85127488881&partnerID=8YFLogxK

U2 - 10.1182/blood.2021013926

DO - 10.1182/blood.2021013926

M3 - Letter

C2 - 35020831

AN - SCOPUS:85127488881

VL - 139

SP - 2252

EP - 2256

JO - Blood

JF - Blood

SN - 0006-4971

IS - 14

ER -

Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this